Remove 2002 Remove Clinical Trials Remove Treatment
article thumbnail

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Cannabis Law Report

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. David Nutt and Prof.

Access 52
article thumbnail

Best strains and terpenes for focus and flow state

The Cannigma

A 2002 study found that cannabis increases blood flow to the frontal lobe of the brain. 11 Multiple clinical trials have shown that linalool in ylang ylang oil and lavender oil, which are both high in linalool “significantly increased calmness” which can help an overactive brain settle down and focus.

Terpenes 122
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

Scientists are hopeful that psychedelics might have more of a curative effect when it comes to mental health than many existing treatment options; meaning that unlike most psychiatric medications, psychedelics may be able to prompt long-term changes to our mental state with only a few doses. Are psychedelics safe?

History 123
article thumbnail

Why we haven’t cured cancer

Otherside Farms

Differential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic pain. Cannabinoids as potential new therapy for the treatment of gliomas. Substance use and survival after treatment for chr… [Am J Drug Alcohol Abuse. news – 2002).

article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. An estimated 4 million to 6 million Americans are on disability because of TBI.

THC 64
article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2002 Jun;42(8):993-1007.

article thumbnail

Green Relief - Untitled Article

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. An estimated 4 million to 6 million Americans are on disability because of TBI.